Marshall University - - Huntington, WV Huntington, WV
Ibrahim Shanti, MD1, Malik Samardali, MD2, Tejas Joshi, MD3, Abdallah Hussein, MD4, Krish Pandya, 5, Wesam Frandah, MD3, Ahmed Sherif, MD3 1Marshall University - - Huntington, WV, Huntington, WV; 2Joan C. Edwards School of Medicine, Marshall University, Huntington, WV; 3Marshall University Joan C. Edwards School of Medicine, Huntington, WV; 4Virtua Our Lady of Lourdes Hospital, Camden, NJ; 5University of Pittsburgh, Newtown, PA Introduction: Background. Decompensated cirrhosis is defined as an acute deterioration in liver function in a patient with cirrhosis and is characterized by jaundice, ascites, hepatic encephalopathy, hepatorenal syndrome or variceal hemorrhage.
The aim of this study was to perform a meta-analysis in order to evaluate the effect of statins on hepatic decompensation in the settings of liver cirrhosis. Methods: Methods. Seven databases were searched to find relevant papers. The quality assessment of observational studies was assessed using the Newcastle–Ottawa scale (NOS) tool. The Comprehensive Meta-Analysis version 3 (Biostat Inc., USA) software was used to conduct the statistical analysis. Pooled hazard ratio (HR) with 95% confidence intervals (CIs) was calculated for hepatic decompensation using random effects. Results: Results. This meta-analysis included seven studies. Overall, the scores of included studies ranged from five to seven stars. Indeed, five were assessed to be of good quality, while two articles were of fair quality. The forest plot revealed that statin treatment was associated with a significant reduction in hepatic decompensation (HR: 0,536; 95% CI: 0,365 to 0,785; p = 0,001). Interestingly, a high heterogeneity was detected across studies: Chi2 = 119,08, p = 0,000, I2 = 94%. Discussion: Conclusions. Our results confirm the beneficial effect of statins in reducing the risk of hepatic decompensation. This result require validation by conducting further studies with a larger sample size.
Figure: Figure 1-A high heterogeneity was detected among studies: Chi2 = 119,08, p = 0,000, I2 = 94%. The forest plot revealed that statin treatment was associated with a significant reduction in hepatic decompensation (HR: 0,536; 95% CI: 0,365 to 0,785; p = 0,001)
Figure: Figure 1-A high heterogeneity was detected among studies: Chi2 = 119,08, p = 0,000, I2 = 94%. The forest plot revealed that statin treatment was associated with a significant reduction in hepatic decompensation (HR: 0,536; 95% CI: 0,365 to 0,785; p = 0,001)
Disclosures: Ibrahim Shanti indicated no relevant financial relationships. Malik Samardali indicated no relevant financial relationships. Tejas Joshi: Salix, Gilead, Echosens – Advisor or Review Panel Member, Consultant, Grant/Research Support. Abdallah Hussein indicated no relevant financial relationships. Krish Pandya indicated no relevant financial relationships. Wesam Frandah: Boston Scientific – Advisor or Review Panel Member, Consultant. Merritt – Consultant. Olympus corporation of America – Consultant. Ahmed Sherif indicated no relevant financial relationships.
Ibrahim Shanti, MD1, Malik Samardali, MD2, Tejas Joshi, MD3, Abdallah Hussein, MD4, Krish Pandya, 5, Wesam Frandah, MD3, Ahmed Sherif, MD3. P5845 - Comprehensive Evaluation of Effect of Statins on Hepatic Decompensation in the Settings of Liver Cirrhosis - Meta-Analysis, ACG 2025 Annual Scientific Meeting Abstracts. Phoenix, AZ: American College of Gastroenterology.
